Efficacy of monoclonal antibodies and maternal vaccination for prophylaxis of respiratory syncytial virus disease
Modeling can be used to reliably predict the efficacy of maternal vaccination for preventing RSV in infants. Passive immunization (e.g., with clesrovimab) is likely to provide more protection for preterm infants and for infants born outside the RSV season than that provided by current maternal vaccines. Maternal vaccination may provide partial protection from RSV disease to full-term infants born just prior to or during the RSV season.
Authors
- Jeffrey R. Sachs (ORCID: https://orcid.org/0000-0001-5725-558X)
- S. Y. Amy Cheung (ORCID: https://orcid.org/0000-0001-5138-7688)
- Nele Plock (ORCID: https://orcid.org/0000-0002-2025-4441)
- Xiaowei Zang (ORCID: https://orcid.org/0000-0002-8319-5303)
- Kalpit A. Vora (ORCID: https://orcid.org/0000-0001-9844-634X)
- Andrew W. Lee
- Brian M. Maas (ORCID: https://orcid.org/0000-0002-2410-4379)
- Jos Lommerse
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Certara (United States) (US)
- UniQure (Netherlands) (NL)
- Netherlands Research School for Literary Studies (NL)
Publication Details
- Journal
- Communications Medicine
- Published
- 2025-04-16
- DOI
- https://doi.org/10.1038/s43856-025-00807-9
- Citations
- 7
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 9.48